Ciongoli Gregory Austin 4

What Happened

• Gregory A. Ciongoli, a director of Atara Biotherapeutics and reported 10% owner, received a grant of 12,000 restricted stock units (RSUs) on 2026-06-09. The award is reported at $0.00 per share (total reported value $0) and is coded as an award/grant (A). This is a compensation-style grant rather than an open-market purchase or sale.

Key Details

• Transaction date and terms: 12,000 RSUs granted on 2026-06-09 at $0.00 per share (reported value $0).
• Vesting: RSUs vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to Mr. Ciongoli’s continuous service (Footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpts.
• Reporting structure: Footnote F2 explains certain securities are held by Adiumentum Capital Fund I LP and related entities; those entities are excluded as reporting persons for this RSU award because they have no pecuniary interest in these RSUs.
• Filing timeliness: Form 4 filed 2026-06-11 for a 2026-06-09 transaction (filed within the typical 2-business-day window).

Context

• RSUs are a deferred-compensation award that typically convert to shares only after vesting and do not involve an immediate cash purchase or sale. Director RSU grants are common as compensation and do not by themselves indicate buying or selling sentiment. Mr. Ciongoli’s 10% ownership and the involvement of Adiumentum (per F2) reflect institutional ownership relationships separate from this personal RSU award.